Pediatric Cardiovascular Drug Dosing in Critically Ill Children and Extracorporeal Membrane Oxygenation
- 1 August 2011
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Cardiovascular Pharmacology
- Vol. 58 (2), 126-132
- https://doi.org/10.1097/fjc.0b013e318213aac2
Abstract
Cardiovascular disease in children is common and results in significant morbidity and mortality. The sickest children with cardiovascular disease may require support with extracorporeal membrane oxygenation (ECMO), which provides life-saving assistance for children with refractory cardiorespiratory failure. Many classes of cardiovascular drugs are used in children, but very few of these agents have been well studied in children. The knowledge gap is even more pronounced in children supported by ECMO. Pharmacokinetic (PK) data collected to date (primarily from antibiotics and sedatives) suggest that the ECMO circuit has the potential to significantly alter the PK of drugs including changes in clearance and volume of distribution. Of all cardiovascular drugs administered to children supported by ECMO, only 11 have been partially studied and reported in the medical literature. Esmolol, amiodarone, nesiritide, bumetanide, sildenafil, and prostaglandin E1 seem to require dosing modifications in children supported by ECMO, whereas it seems that hydralazine, nicardipine, furosemide, epinephrine, and dopamine can be dosed similarly to children not supported by ECMO. However, trials evaluating the PK of these drugs in patients supported by ECMO are extremely limited (ie, case reports), and therefore, definitive dosing recommendations are not plausible. Research efforts should focus on evaluating the PK of drugs in patients on ECMO to avoid therapeutic failures or unnecessary toxicities.Keywords
This publication has 77 references indexed in Scilit:
- Comparison of Shunt Types in the Norwood Procedure for Single-Ventricle LesionsNew England Journal of Medicine, 2010
- Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trialThe Lancet, 2009
- An exploratory study with an adaptive continuous intravenous furosemide regimen in neonates treated with extracorporeal membrane oxygenationCritical Care, 2007
- Pharmacokinetic Changes During Extracorporeal Membrane OxygenationClinical Pharmacokinetics, 2003
- Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenationThe Journal of Pediatrics, 1992
- Cardiovascular and antiarrhythmic effects of esmolol in childrenThe Journal of Pediatrics, 1991
- Effects of hydralazine on cardiac performance in infants receiving extracorporeal membrane oxygenationThe Journal of Pediatrics, 1991
- Clinical Pharmacokinetics and Therapeutic Use of Hydralazine in Congestive Heart FailureClinical Pharmacokinetics, 1989
- Clinical Pharmacokinetics of AmiodaroneClinical Pharmacokinetics, 1984
- Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias.Circulation, 1983